800-671-4304Alcohol Detox Patients Stay Longer When Buprenorphine Starts Fast
Published: 09/29/2026
When someone withdraws from alcohol and opioids at the same time the first 24 hours of a hospital stay may determine whether they stay for treatment.
A study published in the Journal of Addiction Medicine found that psychiatric inpatients who started buprenorphine within a day of admission were far less likely to leave against medical advice than patients who started later or never received the medication.
The finding adds concrete numbers to a growing argument for starting medication assisted treatment as soon as possible even when withdrawal involves more than one substance.
For families researching medical detox the practical message is clear. Timing forms part of treatment rather than serving as a bureaucratic detail.
What the Study Found
Researchers reviewed 332 admissions to an acute psychiatry unit between January 2019 and September 2023. The patients faced a risk of concurrent opioid and alcohol withdrawal.
Just under half of the patients received buprenorphine. That group included 145 patients or 43.7 percent. The researchers grouped patients according to how quickly they started buprenorphine.
Eighty five patients started within 24 hours. Forty four started between 24 and 72 hours. Sixteen started after 72 hours. Another 187 patients never started the medication.
The primary outcome was patient directed discharge. This occurs when a patient leaves before the care team recommends discharge.
Among admissions without buprenorphine 15.5 percent ended in patient directed discharge. The rate fell to 6.9 percent among admissions in which patients received buprenorphine.
Timing made the difference even clearer. Among patients who received the medication 11.4 percent of those who started between 24 and 72 hours left early. Only 5.9 percent of those who started within the first day did so.
Readmission followed a similar pattern. Patients who never started buprenorphine had a 30 day readmission rate of 25.1 percent compared with 11.0 percent among those who received it. At 90 days the rates were 46 percent and 24.1 percent respectively.
The study also tracked whether patients took buprenorphine 90 days later. The authors concluded that starting treatment within 24 hours of admission was associated with lower rates of patient directed discharge and more favorable outcomes for patients and the facility.
The study has important limitations, which is that researchers reviewed past admissions from a single center and used descriptive statistics rather than adjusted comparisons. The findings therefore show an association, rather than proving cause and effect.
Even so the findings align with recommendations from addiction medicine guidelines.
Why Concurrent Withdrawal Is a Distinct Problem
Alcohol withdrawal and opioid withdrawal can each create serious problems. When they occur together they can complicate treatment even further.
Alcohol withdrawal can cause seizures and delirium tremens. Clinicians therefore treat it first with benzodiazepines or other established clinical protocols.
Opioid withdrawal rarely poses a life threatening risk by itself. However it can cause profound discomfort. That discomfort can become a major reason for patients to leave a treatment unit before they complete care.
That issue represents the gap this study addresses. A patient may receive treatment for alcohol withdrawal while opioid withdrawal continues without adequate management. That patient then has a strong reason to leave.
Current ASAM guidance cited in the study’s references recommends stabilizing opioid use disorder with an agonist medication such as buprenorphine while clinicians simultaneously treat alcohol withdrawal. The guidance does not recommend treating the two conditions sequentially.
Understanding Buprenorphine
Buprenorphine acts as a partial opioid agonist. It activates the same receptors as other opioids but produces a lower level of activation. As a result it can relieve withdrawal and cravings without producing the same high or the same overdose risk associated with full agonists.
The FDA has approved three medications for opioid use disorder: buprenorphine methadone and naltrexone. Clinicians can start buprenorphine once a patient shows signs of withdrawal.
The medication also carries a potential complication. If clinicians give buprenorphine too early while other opioids still occupy the receptors it can trigger precipitated withdrawal. That risk explains why clinicians historically waited to start treatment.
This study suggests that in an inpatient setting with appropriate monitoring clinicians also need to consider the potential cost of waiting too long.
Finding Medical Detox
People comparing detox programs near me should ask a direct question before admission. Does the program start medication assisted treatment for opioid use disorder while managing alcohol withdrawal and how quickly does it start?
Programs that treat one type of withdrawal while overlooking the other can leave patients in exactly the situation described in this study.
Never attempt alcohol or benzodiazepine detox without medical supervision. Detox.com lists medical detox programs nationwide. Call 800-996-6135 to find a medically supervised detox program.
